Kaelan Reed

Abstract The next generation of mRNA vaccines must address several limitations, including enhancing vaccine potency and reducing toxicity. Here we develop a class of degradable, cyclic amino ionizable lipids via sequential combinatorial chemistry and rational design.

Immunotherapy is a key component of modern cancer therapy, with more than 40 monoclonal antibody therapeutics and 6 chimeric antigen receptor (CAR)-T cell therapies now approved. Anti-PD1 checkpoint inhibition, for example, has quadrupled 5-year survival rates for patients with advanced non-small cell lung cancer (KEYNOTE-001 trial).